There’s an App for That! Why Risk Calculators Fail to Detect Heart Attacks
Case Presentation
A 52-year-old extremely fit nurse presents to the ER via EMS with accelerating chest pains over several days. She is quite anxious initially and an EKG shows relative sinus tachycardia with ST depressions in the precordial leads.
She is given sublingual nitroglycerin and the chest pain improves — she begins to feel better, her heart rate comes down, and the EKG changes resolve. Her initial high-sensitivity troponin is low at 20, but one hour later it is 27, giving her a "delta" of 7 — above the threshold, suggesting a heart attack in progress.
She is taken urgently to the cath lab where she is found to have a high-grade proximal LAD stenosis of 80%, effectively treated with a drug-eluting (coated) stent.
The Hidden History
The next morning on rounds she expresses gratitude but also frustration and disappointment, given a reassuring workup just four years ago, when she self-referred to a cardiologist out of concern over her family history. Her paternal grandmother had died around the same age from a massive heart attack.
At that visit her LDL cholesterol was 160 mg/dL. The cardiologist prescribed a low-dose statin combined with ezetimibe.
While she wanted to be proactive, she was not enthusiastic about starting statins. A coronary artery calcium (CAC) CT scan was performed, which was reassuringly 0. She had also been following a cardiologist expert on one of the well-known medical media outlets for clinicians, who was not shy about his opinion that statins (or other lipid drugs) were not necessary for younger women despite "high LDL cholesterol." Given this advice, combined with the CAC score of 0, she discontinued lipid-lowering therapy.
However, a month before admission she began having chest pains at the gym and while hiking. She was seen again in the cardiology clinic and a CT angiogram was performed, revealing a high-grade stenosis in the LAD with predominantly noncalcified plaque, similar to the image below.
She was stable at the time and appropriately referred for an outpatient left heart catheterization with coronary angiography, but the symptoms worsened and she called 911.
The Risk Calculator Failure
| Risk Calculator | Estimated 10-Year Risk | Clinical Category |
|---|---|---|
| ACC Pooled Cohort Equation (PCE) | 0.8% | "Low risk" |
| Reynolds Risk Score | 0.4% | "Low risk" |
| ACC Lifetime Risk | 39% | HIGH risk |
Flying Under the Radar
Risk assessment is challenging in young people. It's perhaps most challenging for young women without obvious risk factors. Why? Many reasons, but the most glaring is that most cardiac (ASCVD) risk calculators focus on "10-year" risk — what we consider "short-term" risk. Some offer "lifetime" or "30-year" long-term risk assessment, but these are used far less often.
Let's be honest — we all want simple answers to complex questions. Medicine is no different. To accomplish that, we develop all kinds of tools and calculators in an attempt to make the subjective into objective data points, or to distill an individual down to the lowest common denominator, or to take a large population and pull out the mean (average) characteristics and apply that to the patient sitting in front of us.
While these tools offer us a starting point in risk assessment discussions, our human tendency to rely on them for concrete black-and-white answers leads us astray.
The organizations that generate such calculators want us to use them and use them frequently. "There's even an app for that!" The most commonly employed cardiovascular risk assessment tool is the American College of Cardiology (ACC) Pooled Cohort Equation (PCE) — ASCVD Risk Estimator +.
You can literally pull out the app in front of the patient, plug in some numbers and it (air quotes) "tells you whether to prescribe a statin or not." OK, that's not completely fair — the ACC guideline writers who developed this tool explicitly say it's not a "statin prescription tool." But that's how it often gets employed — and that's exactly how a popular cardiovascular healthcare writer and commentator on "X" phrased it in his rant:
He went on to proclaim that "birthdays" are the main driver of atherosclerosis and heart disease, suggesting that young people don't need to start taking action until the birthdays catch up with them.
What's Misleading About Such a "PSA"
- Expertise questions: While this particular "expert" is a healthcare writer and commentator for a leading online cardiovascular news outlet, his background is electrophysiology and may not have the expertise to make such a "PSA."
- Assumption of clinician ignorance: Who's to say the primary care clinicians didn't use the risk equation as a starting point — like they're advised to do? Again, it's not a "statin prescription tool."
- Factors beyond 10-year risk calculators inform on risk:
- Did you know that the most commonly used risk calculators, such as the ACC's, do not even include family history? The Reynolds CAD Risk Score does — but you will also need to know your C-Reactive Protein (CRP) blood level.
- The Canadian Cardiovascular Society guidelines recommend that estimated risk be doubled when premature family history is present.
- Short-term risk is not very helpful in young people, especially young women:
- Our case patient's 10-year risk by the ACC PCE was 0.8% — low risk. By Reynolds it was 0.4% — again, low risk.
- Her ACC Lifetime Risk? 39%.
- No LDL-C details were provided:
- Presumably their LDL-C was not higher than 190 mg/dL, as the risk calculator does not allow for that and recommends "high-intensity statin." Why 190 mg/dL? Because that's where we start to become concerned about genetic disorders such as Familial Hypercholesterolemia (FH), which is much more common above this threshold and is associated with a 25× higher lifetime risk of ASCVD.
- But was it 189 mg/dL? Was it over 160 mg/dL? Because this is the threshold for potential FH in children and adolescents and can be seen in young adults.
- The 2018 AHA/ACC Guideline on the Management of Blood Cholesterol states that "young adults (20–39 years) with moderate hypercholesterolemia (LDL-C 160–189 mg/dL) may be candidates for cholesterol-lowering drugs, particularly when risk-enhancing factors such as family history of premature ASCVD are present." The guideline notes increased probability of genetic familial hypercholesterolemia in this LDL-C range.
- Assumption that clinicians were wrong: The "PSA" assumes the primary care clinicians did not engage in an individualized "patient-centered discussion with shared decision-making" and were in the wrong.
Even lifetime or 30-year risk may not capture it fully, but it's far better than the 10-year risk calculator alone. Our patient's ACC Lifetime Risk was 39%. The 2013 ACC/AHA Risk Assessment Guideline defines high lifetime risk as over 50% for adults aged 45–50 with ≥2 major risk factors. The European Society of Cardiology defines high lifetime risk using the SCORE2 and SCORE2-OP calculators, where 10-year risk ≥5% but <10% constitutes high risk, while ≥10% represents very high risk.
At what "lifetime risk" threshold does one pull the trigger on lipid-lowering therapy to combat atherosclerosis? The ACC guidelines offer no specific threshold for starting therapy — rather, they feel it can provide context for the potential benefits of lifestyle modification and help motivate therapeutic lifestyle changes. But as our case illustrates, this young woman was already adhering to optimal diet and lifestyle measures. Getting even more aggressive with diet and lifestyle is not likely to impact a disease which relies on "lifetime cumulative exposure to atherogenic lipoproteins."
CardioAdvocate™ Checklist
Baseline Risk Assessment Tools
Family History
Risk Enhancers (2018 ACC/AHA)
Chronic Conditions & Additional Risk Factors
Questions to Ask Your Clinician
Deep Dive
This is a living section — content will be updated as new evidence emerges.
Do Risk Calculators Actually Prevent Events?
The 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults was supposed to be the most evidence-based cholesterol guideline ever written. In fact, the guideline committee was instructed to use only Randomized Controlled Trials (RCTs) or meta-analyses of RCTs. No other data could be entertained in creating recommendations.
Ironically, the Pooled Cohort Equation (PCE) — the risk calculator developed as part of these guidelines — was never validated in any RCT. Meaning, nobody knows whether using this risk calculator actually saves lives or reduces cardiac events. Yet today the PCE is arguably the most widely used ASCVD Risk Estimator. Had they consistently adhered to their own rules, they may have come to the realization that these risk calculators have significant limitations and we wouldn't be using any calculators at all! That's not good either. Just because something hasn't been validated in an RCT doesn't mean it's all bad — you have to start somewhere. But we need to be honest and consistent when evaluating evidence — how we rank it and how we apply it.
Indeed, a 2017 Cochrane systematic review of 41 RCTs involving 194,035 participants found that providing CVD risk scores may have little or no effect on CVD events (5.4% vs 5.3%; RR 1.01, 95% CI 0.95–1.08), though the quality of evidence was low.
In fairness to the guideline writers, they recommended that the Pooled Cohort Equations serve as a starting point for clinician-patient discussion rather than as a "statin prescribing tool" where you plug in data and if the 10-year risk is over 7.5% you write for the statin, and if it's less than 5%, you don't. The guidelines emphasized that PCE estimates must be considered in the context of a particular patient's circumstances when deciding whether to use statin therapy. This recommendation reflected the guideline writers' recognition that because the PCE are population equations, they may overestimate or underestimate risk for individuals or population subgroups.
Unfortunately, many clinicians use that PCE as the be-all end-all. Far from it. We're nowhere near the point where we can put a patient into an app or AI algorithm and it tells us exactly what to do.
How Do We Improve on Risk Calculators?
First, let's ask ourselves what we are trying to accomplish. Most risk calculators are designed to use population data to then lump individual patients into one of three buckets: low, intermediate, and high risk.
Sometimes it's obvious — particularly when it's high risk. For instance, if someone suffers a massive heart attack and lives to tell about it, that's obvious. We throw the kitchen sink at them. They are, after all, our highest-risk patients. We call it "secondary" prevention. It's no longer a secret, but we don't want them to have another event. But it represents a failure. Why? This quote sums it up:
— Huang Dee: Nai Ching (2600 BC, First Chinese Medical Text)
Net Reclassification Improvement (NRI)
The low and intermediate risk patients make up a large population of individuals where "primary" prevention interventions can be invoked. But some of those interventions, particularly drugs, can have drawbacks such as side effects, expense, or variable efficacy across individuals. We're talking about safety, efficacy, and cost.
Patients in low and intermediate risk groups are very heterogeneous (have different characteristics). Some — perhaps many — may be incorrectly classified. Maybe they're high risk and we don't know it (like our patient). Maybe some of them are much lower risk (the 75-year-old female with hypertension and calcium score of 0 who may benefit less from taking that aspirin). So, we need to be more precise. We need to "reclassify" a lot of people — shift some into the high-risk category and shift others down into the low or very-low-risk category.
We call this Net Reclassification Improvement (NRI).
Receiver Operating Characteristic (ROC) Curve and C-Statistic
The ROC curve is the graphical representation and the C-statistic is the area under the curve (AUC). If we were all-knowing, we would be at the upper-left corner and have a C-statistic of 1.0. If we were tossing a coin, we'd be on the diagonal line with a C-statistic of 0.5.
According to the JAMA Users' Guide on Discrimination and Calibration of Clinical Prediction Models: a C-statistic <0.60 reflects poor discrimination, 0.60–0.75 indicates possibly helpful discrimination, and >0.75 suggests clearly useful discrimination.
The Framingham Risk Score (the classic 10-year risk calculator), for instance, has a C-statistic of approximately 0.75–0.80 depending on the population (ACCF/AHA 2007 Clinical Expert Consensus Document on Coronary Artery Calcium Scoring).
When we utilize additional testing, we can either shift the curve upward and to the left if the test helps our predictions, or it may shift it toward the diagonal if it worsens our ability to classify.
What Improves Risk Prediction? NRI Comparison
| Biomarker Added to Model | NRI | C-Statistic Change | Strength |
|---|---|---|---|
| CAC (Coronary Artery Calcium) | 19–66% | +0.04 to +0.16 | Strongest |
| Family History | ~19% | Variable | Strong |
| Lp(a) + Family History | ~21% | +0.004 | Moderate NRI |
| ApoB | 8–11% | Minimal | Modest (best when discordance present) |
| hsCRP | 2–12% | +0.004 to +0.015 | Weakest reclassifier |
CAC vs CRP: Head-to-Head
Coronary artery calcium (CAC) scoring, when added to the Framingham Risk Score, improves the C-statistic by approximately 0.04 to 0.16, with net reclassification improvement (NRI) ranging from 19% to 66%. By contrast, when high-sensitivity C-reactive protein (hsCRP) is added to the Framingham Risk Score it provides minimal improvement in the C-statistic (0.004 to 0.015) and NRI of only 2% to 12% (Evaluation of the Incremental Value of a Coronary Artery Calcium Score Beyond Traditional Cardiovascular Risk Assessment: A Systematic Review and Meta-analysis — JAMA Internal Medicine).
The Multi-Ethnic Study of Atherosclerosis (MESA) directly evaluated both markers in 1,330 intermediate-risk individuals (Comparison of Novel Risk Markers for Improvement in Cardiovascular Risk Assessment — JAMA):
CAC improved C-statistic from 0.623 → 0.784 (change: +0.161), NRI 65.9%, HR 2.60 (95% CI 1.94–3.50).
hsCRP improved C-statistic from 0.623 → 0.640 (change: +0.017), NRI 7.9%, HR 1.28 (95% CI 1.00–1.64, borderline).
CAC reclassified nearly 10 times more patients correctly than CRP.
CRP showed only borderline statistical significance for coronary heart disease prediction (High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?).
ApoB: When LDL-C Misleads
As mentioned throughout this site, ApoB improves upon LDL-C as a biomarker for atherosclerosis due to the fact that all atherogenic particles contain exactly one ApoB molecule. LDL cholesterol concentration is a surrogate for LDL particles, which means it can be discordant at times, particularly when individuals have high triglycerides and low HDL cholesterol. We see this most often with disorders related to insulin resistance and obesity, such as metabolic syndrome, diabetes, prediabetes, and fatty liver disease.
In those patients, LDL-C underestimates LDL particles and therefore underestimates risk. Discordance can also go in the other direction — where LDL-C is represented in relatively fewer, larger LDL particles. In that case, ApoB will be relatively lower. When ApoB and LDL-C are discordant, risk tracks better with ApoB.
When added to risk prediction models using standard lipid biomarkers, the C-statistic changes minimally but the NRI is influenced modestly at 8–11%. Obviously this varies depending on the population. When added to a general population, ApoB isn't much better than LDL-C — that makes sense when they're concordant. But when added to a population with discordance, ApoB improves prediction. The worse the discordance, the better ApoB improves upon LDL-C (Lipid-Related Markers and Cardiovascular Disease Prediction — JAMA).
Family History: The Free Risk Enhancer
Family history of premature ASCVD is typically defined as events in first-degree relatives (parent, sibling, and even offspring) at young ages (males <55 years, females <65 years). This has been shown to increase risk 1.5–2.0×, hence the rationale for the Canadian Cardiovascular Society recommendation to double risk estimates when premature family history of ASCVD is present (2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults).
The Dallas Heart Study and the Multi-Ethnic Study of Atherosclerosis (MESA) showed an NRI of ~19% when family history is added to risk prediction models.
Lipoprotein(a): The Genetic Wild Card
Given that Lp(a) is approximately 90% genetically determined by the LPA gene and elevated levels (at or above 125 nmol/L or 50 mg/dL) are present, by definition, in 1 in 5 families, it's not surprising that family history performs even better when Lp(a) is also elevated — increasing the C-statistic by 0.004 and achieving an NRI of ~21% (Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk). This is a factor that standard risk calculators completely ignore.
30-Year and Lifetime Risk Models
Thirty-year risk models have been found to be better than 10-year models, with C-statistics of 0.738–0.755 for the 30-year models compared to 0.726 for the 10-year model. The expanded cardiovascular disease outcome model had the highest C-statistic of 0.755 (95% CI 0.720–0.789) — a statistically significant improvement of 0.028 (95% CI 0.001–0.053) compared to the 10-year model (Incidence of Atherosclerotic Cardiovascular Disease in Young Adults at Low Short-Term But High Long-Term Risk).
The NRI also reclassified 16% of young adults.
The 2013 ACC/AHA Risk Assessment Guideline writers intended the 30-year risk calculator to be used as a supplement to the 10-year risk in younger adults, because younger adults tend to have lower predicted risk despite having risk factors. Basically, age does impact risk tremendously because it reflects one's cumulative exposure to risk factors. So, an individual may be looking at a high lifetime trajectory but the risk calculators will underestimate that outlook in a young person, giving them a false sense of security.
Thirty-year risk calculators help account for this underestimation to a degree, but still aren't perfect. The lifetime risk calculation, as recommended by the 2018 cholesterol guideline, requires an age of 45 and older. If you're in the 20–39 age group, you must extrapolate (Managing Atherosclerotic Cardiovascular Risk in Young Adults: JACC State-of-the-Art Review).
Notably, the same analysis showed that 40% of young adults with low 10-year risk were classified as high lifetime risk, compared with only 1.6% with 30-year risk. The difference is due to using a continuous risk scale versus using five categories, respectively.
JACC Focus: A Life-Course Approach to Cholesterol in Women (February 2026)
The February 2026 JACC Focus Issue on Women's Cardiovascular Health includes a Viewpoint by Dr. Michael Honigberg that directly validates the concerns raised by our case patient — and this article. His central argument: we must move beyond short-term, age-driven risk calculators toward a life-course approach that accounts for cumulative exposure to atherogenic lipoproteins.
- 10-year risk calculators underestimate lifetime burden in young women — exactly the failure our 52-year-old patient experienced at age 48
- Statin decisions should account for reproductive goals and pregnancy planning
- Shared decision-making needs individualization, not rigid calculator thresholds
This reversal occurred during the very period when risk calculators and guidelines should have been improving outcomes. Instead, the data suggests we are missing the mark on primary prevention in the populations most failed by 10-year risk calculators: young adults and women.
A "Uniquely American" Crisis (Harvard / JACC Stats 2026)
A Harvard Gazette analysis of the inaugural JACC Cardiovascular Statistics 2026 report underscores the systemic nature of this failure:
- One in two U.S. adults has high blood pressure — with little change since 2009
- Only two in three adults with hypertension receive treatment
- Hypertension-related CV deaths nearly doubled from 2000–2019 (23 to 43 per 100,000)
"Many other higher-income countries are grappling with rising obesity and diabetes, but the U.S. stands out for how consistently those risks translate into worse cardiovascular outcomes, and how wide the gaps are by income, race, ethnicity, and geography." — Dr. Rishi Wadhera, Harvard.
Enhanced HEART Score: Improving Acute Chest Pain Assessment
A new study published in the Journal of Clinical Medicine from Centro Cardiologico Monzino demonstrates that adding clinical and laboratory variables to the traditional HEART score significantly improves prediction of significant coronary artery disease on CT angiography (CCTA).
The standard HEART score performance in this cohort revealed an important gap:
| HEART Score Category | % of Cohort | Positive CCTA |
|---|---|---|
| Low risk | 27% | 7% had significant CAD |
| Moderate risk | 67% | 27% had significant CAD |
| High risk | 6% | 67% had significant CAD |
The enhanced model, which incorporated additional clinical and laboratory variables, significantly improved AUC and net reclassification — particularly in the low-to-moderate risk groups where clinical uncertainty is greatest.
Limitations: This was a single-center retrospective study. A positive CCTA does not necessarily equal ACS diagnosis or revascularization need. Coronary calcium and plaque phenotype were not included in the enhanced model.
The broader lesson aligns with the theme of this article: risk stratification tools should guide — not replace — clinical judgment. Patient-centered decision-making integrates pretest probability, local resources, and individual preferences.
Related CardioAdvocate Content
The strongest single reclassifier of cardiovascular risk. Our case patient had a CAC of 0 but developed significant noncalcified plaque.
When LDL-C alone doesn't tell the whole story — why ApoB matters for risk prediction.
The genetic risk factor that standard risk calculators completely ignore.
When LDL-C of 160+ signals a genetic condition — our case patient's LDL-C of 160 mg/dL should have raised this concern.
Where CRP fits in risk assessment — and its limitations as a reclassifier compared to CAC.
When high triglycerides, low HDL-C, and small dense LDL particles create discordance between LDL-C and ApoB.
Insulin resistance and metabolic syndrome are risk enhancers that calculators underweight.
Sex-specific risk factors and why risk calculators systematically fail young women.
Preeclampsia, gestational HTN, and gestational diabetes as risk enhancers for future ASCVD.
When risk assessment suggests referral to a preventive cardiologist or lipid specialist.
Understanding the strengths and limitations of cardiovascular risk prediction tools.
The Bottom Line
- Birthdays don't cause atherosclerosis. Lifetime cumulative exposure to atherogenic lipoproteins does.
- "Normal" cholesterol is plenty capable of causing the disease of atherosclerosis. In individuals, one can have "high cholesterol" and never develop atherosclerosis, and one can have "normal" or even "low" cholesterol and develop it.
- The greater the exposure to atherogenic lipoproteins (as LDL-C indicates), the greater the risk of disease.
- Risk calculators are starting points, not final answers — they do a relatively poor job of predicting heart attack, but they are a place to begin risk assessment.
- 10-year risk systematically fails young patients and women.
- Family history, Lp(a), ApoB, and CAC are not adequately captured by standard tools.
- CAC is the strongest single reclassifier of cardiovascular risk — reclassifying nearly 10× more patients correctly than CRP.
- ~75% of first MI patients would not have qualified for statins the day before their event.
- A lifetime risk of 39% is not "low risk" — regardless of what the 10-year calculator says.
- February 2026 data confirms the gap is widening: Young adult MI deaths are rising (women hit hardest), JACC Stats 2026 shows implementation has stalled, and a JACC Focus Issue calls for abandoning rigid 10-year risk calculators in favor of a life-course approach — especially for women.
